China's Biopharma Industry Expects 27% Annual Growth In 2011-15
This article was originally published in PharmAsia News
Executive Summary
China's biopharmaceutical industry will see annual growth of 27% during the country's 12th Five-Year Plan period, according to the forecast of a security firm, driving dozens of Chinese drug companies to try to grab a piece of the market